Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2005
10/20/2005WO2005097996A1 Novel mite allergen
10/20/2005WO2005097993A2 Immunostimulatory viral rna oligonucleotides
10/20/2005WO2005097987A1 Antiinfection vaccine antigen for mucosa-directional human papillomavirus group
10/20/2005WO2005097976A1 Dendritic cell obtained by antigen pulsing
10/20/2005WO2005097832A2 Humanized anti-tgf-beta antibodies
10/20/2005WO2005097823A1 Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotherapy
10/20/2005WO2005097822A1 Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
10/20/2005WO2005097211A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005WO2005097204A1 Preventives/remedies for cancer
10/20/2005WO2005097189A1 Carcinoma cell-specific apoptosis inducing agent targeting gene relevant to chromosome stabilization
10/20/2005WO2005097188A2 Method to decrease the risk of a vaccine-induced chronic immune mediated disorder in humans with a family history of the disorder
10/20/2005WO2005097187A2 Methods of preventing uvb-induced skin damage
10/20/2005WO2005097186A2 Bioactive stents for type ii diabetics and methods for use thereof
10/20/2005WO2005097185A2 Irta-5 antibodies and their uses
10/20/2005WO2005097184A2 Antibodies against nogo receptor
10/20/2005WO2005097183A2 Treatment of diseases
10/20/2005WO2005097182A1 Antigen-drug vehicle enabling transmucosal and transdermal administration and method of inducing mucosal immunity, mucosal vaccine and dds using the same
10/20/2005WO2005097181A1 Microfluidized oil-in-water emulsions and vaccine compositions
10/20/2005WO2005097180A1 Dimeric tat antigen and the use thereof for anti-hiv vaccination
10/20/2005WO2005097179A2 Stabilised tat antigen and the use thereof for anti-hiv vaccination
10/20/2005WO2005097169A2 Novel immunotherapy
10/20/2005WO2005097165A2 Il-28 and il-29 cysteine mutants for treating viral infection
10/20/2005WO2005097162A2 Steroid sparing agents and their use
10/20/2005WO2005097121A1 Angiogenesis-affecting compounds and methods of use thereof
10/20/2005WO2005097086A2 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
10/20/2005WO2005096823A1 Vaccine for nontypeable haemophilus influenzae infection
10/20/2005WO2005096806A1 Rice plant having vaccine gene transferred thereinto
10/20/2005WO2005065708A3 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
10/20/2005WO2005060520A3 ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
10/20/2005WO2005049641A3 Surface-located campylobacter jejuni polypeptides
10/20/2005WO2005028505A3 Multiepitope polypeptides for cancer immunotherapy
10/20/2005WO2005020923A3 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
10/20/2005WO2005005603A3 Method for inducing an immune response to cancer antigen
10/20/2005WO2004096157A3 Treatment of igai deposition diseases
10/20/2005WO2002097033A3 Antibodies that immunospecifically bind to trail receptors
10/20/2005US20050235371 Noval modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
10/20/2005US20050234247 New effector conjugates, process for their production and their pharmaceutical use
10/20/2005US20050234225 Comprising complementarity determining regions; recombinant host cells; fab fragments, fv fragments, diabodies, triabodies, and single domain antibodies; angiogenesis inhibitors; antitumor, antiproliferative, and anticarcinogenic agents; gene expression
10/20/2005US20050234222 Polypeptide comprising at least one alpha-helix having synthetically attached thereto a plurality of therapeutic or diagnostic moieties
10/20/2005US20050234080 Mitotic kinesin inhibitors
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234010 Novel branched sialo-sugar molecules and antiviral agents using the same
10/20/2005US20050234004 Compositions and methods of use of W-peptides
10/20/2005US20050233999 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
10/20/2005US20050233995 Immunostimulatory nucleic acid molecules
10/20/2005US20050233992 Regeneration of endogeneous myocardial tissue by induction of neovascularization
10/20/2005US20050233991 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
10/20/2005US20050233989 Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
10/20/2005US20050233948 Drug complex for treatment of metastatic prostate cancer
10/20/2005US20050233451 Stimulating peripheral blood mononuclear cells in vitro with antigen, transducing with retroviral vector and reintroducing into patient
10/20/2005US20050233435 Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
10/20/2005US20050233408 Modified bacterial surface layer proteins
10/20/2005US20050233385 Using antibodies on cell surfaces
10/20/2005US20050233350 Method for typing of minor histocompatibility antigen HA-1
10/20/2005US20050233316 Monoclonal antibody for diagnosis, prevention and treatment of viral infections; immunotherapy
10/20/2005US20050233301 Cryopreservation of haptenized tumor cells
10/20/2005US20050232966 implants containing a neurotoxin with sustained biological activity would manifest as improved patient compliance, increased quality of life, improved therapeutic outcome and a reduced incidence of side effects and complications
10/20/2005US20050232951 Low dose haptenized tumor cell and tumor cell extract immunotherapy
10/20/2005US20050232950 Viruses comprising mutant ion channel protein
10/20/2005US20050232949 transgenic edible plants comprising a nucleotide construct, including promoters that preferentially targets expression to an edible tissue of the plant and untranslated signal sequences, that codes an immunogen of a recombinant animal viral antigen protein, that induces an immune responses
10/20/2005US20050232948 Adjuvanted vaccine which is substantially free of non-host albumin
10/20/2005US20050232947 Bacterial spores
10/20/2005US20050232946 Vaccine against microbial pathogens
10/20/2005US20050232943 Antigenic composition of a Pseudomonas aeruginosa protein
10/20/2005US20050232942 Virulence genes, proteins, and their use
10/20/2005US20050232941 Compounds and methods for treatment and diagnosis of chlamydial infection
10/20/2005US20050232940 Recombinant plasmid and a method of controlling the effects of yersinia pestis
10/20/2005US20050232939 Novel therapeutic compositions for treating infection by Lawsonia spp.
10/20/2005US20050232938 Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection
10/20/2005US20050232937 Paramycobacterial diagnostics and vaccines
10/20/2005US20050232936 Meningococcus adhesins nada, app and orf 40
10/20/2005US20050232935 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
10/20/2005US20050232934 Recombinant reverse transcriptases
10/20/2005US20050232933 CMV-IE1 peptides and method of use
10/20/2005US20050232932 Compositions and methods for dendritic cell-based immunotherapy
10/20/2005US20050232931 Chimeric protein; induction apoptosis; anticancer agents; vaccine
10/20/2005US20050232930 Processes for the preparation of a batch of an active pharmaceutical ingredient, a container comprising cryogranules of an allergen product, and a cryogranule of an allergen product
10/20/2005US20050232929 detect, screen, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates, antibodies, and fragments and metabolites thereof, by affinity separation, chromatography, and mass spectrometry; monomethyl auristatin drug and a thio-ether linkage
10/20/2005US20050232928 Drug conjugates
10/20/2005US20050232927 Using notch gene expression as evaluative tool in detecting breast cancer
10/20/2005US20050232926 Expressed in melanoma, breast cancer and hepatocellular carcinoma; fab fragments; fv fragments; competitive binding; for inducing caspase mediated apoptosis; neoplasm diagnosis
10/20/2005US20050232925 Protease activity of thrombin inhibits angiogenesis
10/20/2005US20050232924 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
10/20/2005US20050232923 Methods and compositions for treating MCP-1 related pathologies
10/20/2005US20050232922 Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
10/20/2005US20050232921 Immunoglobulin mixture specific to endothelial growth factor for use as tools in treatment and prevention of cell prolifreative disorders; antitumor agents
10/20/2005US20050232920 Inhibition of complement activation
10/20/2005US20050232919 Monoclonal antibodies that specifically block biological activity of a tumor antigen
10/20/2005US20050232918 Differentially expressed genes associated with obesity and type 2 diabetes
10/20/2005US20050232917 Antibodies to MAdCAM
10/20/2005US20050232906 Adjuvant preparation for the induction of specific immunity
10/20/2005US20050232904 Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
10/20/2005US20050232897 Mucosal cytotoxic T lymphocyte responses
10/20/2005CA2799469A1 Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
10/20/2005CA2579710A1 Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same
10/20/2005CA2563887A1 Mite allergen zen 1
10/20/2005CA2563313A1 Modulation of nkg2d
10/20/2005CA2562385A1 Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
10/20/2005CA2562223A1 Treatment of autoimmune disorders of the skin with a goat serum obtained from a goat challenged with hiv immunogen
10/20/2005CA2562018A1 Bioactive stents for type ii diabetics and methods for use thereof
1 ... 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 ... 1823